Australian Productivity Commission investigates IP arrangements

12 November 2015

Australia’s Productivity Commission today announced an Inquiry to consider whether current intellectual property (IP) arrangements provide an appropriate balance between access to ideas and products, and encouraging innovation and investment.

In recommending changes to the current system to improve the overall wellbeing of Australian society, the Commission will consider:

• incentives for innovation and investment, including freedom to build on existing innovation;
• Australia's international trade obligations;
• the relative contribution of IP to the Australian economy;
• the economy-wide and distributional consequences of recommendations, including their impacts on trade and competition;
• ensuring the IP system will be efficient and robust through time, in light of economic changes;
• how proposed changes fit with, or may require changes to, other existing regulation or forms of assistance;
• the relevant findings and recommendations of recently completed reviews.

The consultation closes November 30, 2015. The draft report is expected to be released in March or April 2016, at which point the Commission will seek further information and feedback. The Commission’s report is expected to be handed to the Australian government in August 2016.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical